Clinical Trials Logo
  1. Home
  2. Thrombotic Microangiopathies
  3. NCT04745195

Complement Prospective Evaluation of Thrombotic Microangiopathy on Endothelium — COMPETE  

Thrombotic Microangiopathies Clinical Trial

Official title:
Diagnostic and Risk Criteria for Complement Defects in Thrombotic Microangiopathy and Amplifying Conditions, Such as Severe Hypertension: The COMPETE Study.

Clinical Trial Summary

Thrombotic microangiopathy (TMA) is a severe and life-threatening condition, often affecting the kidneys and brain. It can occur on the background of various clinical conditions. Dysregulation of the alternative pathway of complement may be the etiological factor and this type of TMA is classified, according to the current nomenclature, as primary atypical hemolytic uremic syndrome (HUS). Half the patients with primary atypical HUS present with rare variants in complement genes, although coexisting conditions are often needed for the TMA to become manifest. In patients with secondary atypical HUS, certain coexisting conditions appear to drive the disease and treatment should target the underlying condition to remit the TMA. Recently, the investigators demonstrated, by using a novel in-house developed functional endothelial cell-based test, that complement dysregulation and overactivation is the dominant cause of disease and its sequelae in a subset of patients with secondary atypical HUS, having impact on treatment and prognosis. The investigators did first prove this concept in patients presenting with TMA and hypertensive emergency. A prospective study is needed to further corroborate these findings along the spectrum of TMA. The investigators hypothesize that their functional endothelial cell-based test, the so-called "HMEC" test, can better categorizes the TMA into different groups with potential therapeutic and prognostic implications. Thus, paving the road to the ultimate goal of precision medicine.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04745195
Study type Observational [Patient Registry]
Source Maastricht University Medical Center
Contact Pieter van Paassen, MD, PhD
Phone +31(0)433871198
Email p.vanpaassen@maastrichtuniversity.nl
Status Recruiting
Phase
Start date August 12, 2021
Completion date August 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04098445 - TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients
Recruiting NCT03605511 - TTP and aHUS in Complicated Pregnancies
Not yet recruiting NCT05996679 - Automated Surveillance, Alert, and Rapid Diagnosis of Thrombotic Microangiopathies: the ASARD-TMA Study
Completed NCT02222545 - Safety and Efficacy Study of OMS721 in Patients With Thrombotic Microangiopathies Phase 2
Recruiting NCT06102694 - Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
Completed NCT03252925 - A Safety and Efficacy Study of NAC in Patients With TA-TMA Phase 3
Not yet recruiting NCT06182410 - Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma Phase 2
Recruiting NCT05855083 - Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA Phase 2
Completed NCT03384693 - Defibrotide TMA Prophylaxis Pilot Trial Phase 2
Not yet recruiting NCT06291415 - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) Phase 1
Not yet recruiting NCT05702996 - Multicenter, Uncontrolled Pilot Study Evaluating the Efficacy of Eculizumab in the Treatment of Gemcitabine-induced Thrombotic Microangiopathies Phase 3
Not yet recruiting NCT02373267 - Screening of TMA Patients für ADAMTS13 Activity (Adamscreen) N/A
Recruiting NCT06098378 - Study of Patients With Thrombotic Microangiopathy Associated With Mitomycin C, Treated or Not With Eculizumab
Completed NCT02134171 - Early Predictive Factors of Cardiac and Cerebral Involvement in TMA N/A
Withdrawn NCT04970004 - Study in Adult and Pediatric Patients With HSCT-TMA
Recruiting NCT03205995 - Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome Phase 3
Recruiting NCT04784455 - Nomacopan (rVA576) in Transplant Associated Thrombotic Microangiopathy Phase 3
Active, not recruiting NCT04570397 - Ravulizumab and COVID-19 Phase 3
Recruiting NCT05634928 - Construction of a Database for TMA
Completed NCT03518203 - Eculizumab to Treat Thrombotic Microangiopathy/Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients Phase 2